KIT Inhibition by Imatinib Helps Severe Refractory Asthma

KIT Inhibition by Imatinib Helps Severe Refractory Asthma

MONDAY, May 22, 2017 (HealthDay News) — Imatinib (Gleevec) may effectively treat severe refractory asthma, according to research published in the May 18 issue of the New England Journal of Medicine.

Elliot Israel, M.D., director of the respiratory therapy department at Brigham and Women’s Hospital in Boston, and colleagues recruited 62 patients with poorly controlled severe asthma with airway hyperresponsiveness despite maximal medical therapy. All were randomly assigned to take either imatinib or a placebo pill once daily during the six-month trial.

The researchers found that imatinib was associated with a reduction in mast-cell activity. Allergy challenge tests demonstrated a decrease in airway reactivity among patients taking imatinib. Side effects in the intervention group included muscle cramps and hypophosphatemia.

“In patients with severe asthma, imatinib decreased airway hyperresponsiveness, mast-cell counts, and tryptase release,” the authors write. “These results suggest that KIT-dependent processes and mast cells contribute to the pathobiologic basis of severe asthma.”

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures imatinib and provided the drug for the study free of charge.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen − 7 =